
Diabetic Macular Edema
Latest News
Video Series

Shorts




CME Content

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Second phase 3 trial of Duravyu misses wet AMD noninferiority end point; EyePoint cuts 53% of staff to focus on DME.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.

AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.

Key takeaways on gene therapy, GA, sustained delivery and AI in Vienna

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

4DMT's 4D-150 gene therapy enters phase 3 4SIGHT trial in DME; 2-year SPECTRA data show +10.8-letter BCVA gain in 9 patients.

Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial
Remigromig met its BRUNELLO primary end point in DME, with higher PDR and vitreous hemorrhage rates than ranibizumab.

Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.

Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.

Kodiak fully enrolled the first pivotal cohort of its phase 3 PEAK trial testing KSI-101 for inflammatory macular edema, with topline data expected December 2026.

EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.

A recap of the FDA approvals, phase 3 readouts, and pipeline data that shaped diabetic eye disease care in the first half of 2026.

Three cases illustrate how next-generation anti-VEGF agents are extending treatment intervals and improving durability across retinal vascular disease.

Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients.

FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes
The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.

Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.























